Immuneering (IMRX) to Release Quarterly Earnings on Tuesday

Immuneering (NASDAQ:IMRX - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter.

Immuneering (NASDAQ:IMRX - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.16). On average, analysts expect Immuneering to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Immuneering Stock Down 3.9 %

Immuneering stock traded down $0.05 during mid-day trading on Friday, reaching $1.24. 188,762 shares of the company's stock traded hands, compared to its average volume of 2,347,634. The stock has a 50 day moving average of $1.47 and a two-hundred day moving average of $1.82. Immuneering has a 12-month low of $1.00 and a 12-month high of $3.83. The company has a market cap of $44.62 million, a price-to-earnings ratio of -0.63 and a beta of -0.25.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Needham & Company LLC reiterated a "buy" rating and issued a $12.00 price target on shares of Immuneering in a report on Thursday, April 10th. Chardan Capital restated a "buy" rating and issued a $13.00 price target on shares of Immuneering in a report on Monday, March 24th.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.